Verapamil - Eisai

Drug Profile

Verapamil - Eisai

Alternative Names: E-0103; Vasolan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer Eisai Co Ltd
  • Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Ischaemic heart disorders; Paroxysmal supraventricular tachycardia; Supraventricular tachycardia

Most Recent Events

  • 21 Mar 2013 Chemical structure added (USAN); str saved as MOL and PNG files
  • 21 May 2011 Registered for Supraventricular tachycardia in Japan (PO)
  • 20 May 2011 Registered for Supraventricular tachycardia in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top